Seraphina Therapeutics, the company behind the human supplement Fatty15, expanded into pet health with Longevity15, a pentadecanoic acid (C15) product marketed for dogs. The pitch mirrors the human product: C15 is framed as a newly identified essential fatty acid that supports cell membrane stability and healthy aging, this time for a four-legged audience.
Before assuming the human evidence simply carries over, it’s worth separating what has actually been studied from what is being extrapolated. This article looks at the human and animal research that exists, is honest about what’s missing (namely, a published, peer-reviewed clinical trial in dogs) and explains what pet owners are realistically buying into.
What Longevity15 Is Actually Selling
Longevity15 is a pentadecanoic acid supplement dosed for dog body weight, sold by Pets Best Life in partnership with Seraphina Therapeutics. The product page lists the active ingredient as FA15, the name Fatty15 uses for its capsule ingredient, though it does not state the amount per packet. The marketing case draws directly on the human research base: C15’s association with lower rates of metabolic and inflammatory disease markers in circulating-blood studies, and its proposed role in stabilizing cell membranes against a form of cell death called ferroptosis [1].
That lineage is worth naming plainly. The company is not citing a dog-specific clinical trial because, as of this writing, no peer-reviewed veterinary trial of C15 supplementation has been published. The product’s scientific basis is entirely extrapolated from human and preclinical rodent data.
What the Underlying Human and Animal Research Actually Shows
The strongest piece of direct clinical evidence for C15 is a small randomized, double-blind, placebo-controlled trial, supported by Seraphina Therapeutics, in 30 young adults with overweight or obesity [2], who took 200 mg of C15 or a placebo daily for 12 weeks. Circulating C15 rose significantly more in the treatment group, and no significant adverse events were reported [2]. Participants who reached higher circulating C15 levels post-treatment also saw larger reductions in liver enzymes and a rise in hemoglobin: a post-hoc subgroup signal worth further study, not a proven clinical outcome; apart from one liver enzyme, the trial found no other significant differences from placebo in its secondary outcomes [2].
Research note: In rats, a ~30% rise in dietary total fat produced a ~35% drop in circulating C15:0 [9].
On the animal side, the most relevant published work is a rat study examining C15 supplementation in essential-fatty-acid-deficient animals at weaning, which found effects on the profile of a newly described class of odd-chain PUFAs [3]. That’s a rodent nutritional-deficiency model, not a companion-animal supplementation trial, and rats and dogs differ meaningfully in fat metabolism.
Cell-based work by authors linked to the C15 supplement maker has also compared C15’s anti-inflammatory activity favorably to EPA [4], a well-studied omega-3, across a panel of human cell systems [4]. Cell assays are useful for generating hypotheses about mechanism; they are not evidence that a dog eating a capsule will show the same effects in vivo.
What’s Missing for Pet Owners Specifically
No published trial has measured whether oral C15 supplementation changes circulating C15 levels in dogs, what an appropriate weight-based dose is, or whether any of the metabolic or membrane-stability signals seen in human cells and rodent models translate to observable health outcomes in companion animals. Canine fat metabolism, gut absorption, and typical diet composition differ from the human case Fatty15 was originally built around.
None of this means the ingredient is unsafe for dogs: C15 is a fatty acid found naturally in the diet (although Fatty15 says its capsule ingredient is synthesized to match the natural form), and the only human supplementation trial, which was supported by the supplement maker, reported no significant adverse events at 200 mg a day over 12 weeks in 30 adults (nothing is known for dogs) [2][2]. But ‘naturally occurring and well-tolerated in a small human trial’ is a different claim than ‘proven to help your dog age better,’ and pet owners are currently being asked to trust the extrapolation rather than a direct study.
Should You Try It for Your Dog?
If you’re considering a C15 supplement for a pet, the honest framing is that you’re paying for a hypothesis extended from human and rodent data, not a veterinary-trial-backed product. That’s not unusual in the pet supplement space, most companion-animal nutraceuticals launch on adjacent human evidence before dedicated animal trials catch up, but it’s worth knowing going in, and worth asking your veterinarian before adding any new supplement to a dog’s diet, particularly for animals with existing liver, kidney, or metabolic conditions.
What the Longevity15 Product Page Actually Lists
The Pet’s Best Life product page for Longevity15, read in October 2026, gives a few verifiable specifics. Each box holds 30 packets, with five weight bands: extra small (5.5 to 12 lb), small (13 to 25 lb), medium (26 to 50 lb), large (51 to 100 lb) and extra large (over 100 lb). The active ingredient is listed as FA15 (pentadecanoic acid), and the inactive ingredients are Himalayan cheese, miscanthus grass, natural flavoring and mixed tocopherols as a preservative. The feeding instruction is one packet a day at mealtime. The page offered a one-time purchase or a subscription with a 10 percent discount shipping every 30 days, a 60-day money-back promise, and prices that vary by size and change over time.
Two things the page text did not state are worth noting. The amount of pentadecanoic acid per packet, in milligrams, was not listed in the text read, which makes it hard to compare against the 100 mg in a human Fatty15 capsule or against the 200 mg used in the human trial. And while the page calls the formula clinically researched, the product’s launch announcement, as published on PRWeb, cites no dog study. It instead argues that aging mechanisms are shared across mammals, and the only dog clinical data it mentions belongs to an unrelated dental treat. That is a marketing argument, not a trial result.
Searching the Literature for Dog Data
A PubMed search in October 2026 for pentadecanoic acid combined with dog and canine terms returned no supplementation, safety or efficacy study in dogs. The few hits were older nuclear-medicine papers that used radioiodinated pentadecanoic acid analogs as heart-imaging tracers in canine models, which concern tracer chemistry and tell us nothing about whether a daily capsule helps a pet. Searches for odd-chain fatty acid levels in dog plasma also found nothing relevant. Absence in a search is not proof that no such work exists, since unpublished or company-held data may be out there, but it does mean a pet owner cannot check a dog trial for themselves.
Where the C15 Idea Came From: Dolphins, Not Dogs
Fatty15’s own FAQ says the discovery began with the work of Stephanie Venn-Watson, a veterinary epidemiologist, who noticed that the healthiest aging dolphins had higher C15 levels in their diets. The same research thread continues: a 2025 paper in the International Journal of Molecular Sciences (Venn-Watson and Jensen) examined archived brain tissue from 19 Navy dolphins, finding amyloid plaques and neuroinflammation that increased with age in the hippocampus. In a separate third-party screening panel, C15 inhibited two enzyme targets in a dose-dependent way, fatty acid amide hydrolase and monoamine oxidase B. The authors suggest C15 may support cognitive health, and the paper discloses that the first author co-founded the companies that hold the commercial licensing rights. This is correlational and biochemical work in dolphins and in test-tube assays. It is not a study of dogs, and it does not show that eating C15 changes a dog’s brain.
The C15 idea grew from dolphin work, and none of the evidence here is from dogs
Lower C17:0 with higher insulin
Serum C17:0 was 0.3% in the higher-insulin group and 1.3% in the lower-insulin group. This is C17:0, not C15:0.
Extra fish, more C17:0
Over 24 weeks, daily C17:0 intake went from 400 to 1700 mg, serum C17:0 rose and high ferritin fell.
No harm seen at 15% of diet
An algal oil made mostly of C15:0 and C17:0 had no observed adverse effects at up to 15% of the diet.
For a dog owner, the honest summary is dolphin hints and rat safety data, with no dog trial.
The dolphin work is industry-funded and the animals were few. Rat safety data are not a dose guide for pets. Source: PLoS ONE 2015; Food and Chemical Toxicology 2021.
Chart: c15hub.com: The C15 idea grew from dolphin work, and none of the evidence here is from dogs
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
Human, Rat and Cell Data in Their Proper Place
If you are comparing evidence, here is where each piece sits. The human randomized trial in the Journal of Nutrition (Robinson et al., 2024) used 200 mg daily for 12 weeks in 30 young adults with overweight or obesity and found higher circulating C15, no significant adverse events, and exploratory improvements in liver enzymes and hemoglobin in people who reached higher blood levels. A 2021 safety evaluation in Food and Chemical Toxicology (Matulka et al.) tested an odd-chain algal oil made mostly of pentadecanoic and heptadecanoic acids in rats for 13 weeks at up to 15 percent of the diet, and reported no adverse effects and no genotoxicity, which supports that odd-chain fatty acids are tolerated in rodents at high dietary levels. It was a different material from the pure powder in Longevity15 and a different species. A 2025 rat study in the Journal of Nutritional Biochemistry found that, in rats fed an essential-fatty-acid-deficient diet from weaning, adding pentadecanoic acid improved early growth compared with staying deficient and led to previously undescribed odd-chain polyunsaturated fatty acids. The authors describe this as possibly counteracting the growth delay, with the mechanism still to be worked out. None of these used dogs.
Species Differences That Matter
Whether a dog needs supplemental C15 depends on facts that have not been established. A 2016 review in Advances in Nutrition (Pfeuffer and Jaudszus) notes that in humans, odd-chain fatty acids such as pentadecanoic acid can also be produced in the body from gut-derived propionic acid, not only taken in through dairy fat. Whether and how much dogs do this, how much their usual food provides, and what a typical blood level is in healthy dogs of different breeds and ages are open questions in the sources reviewed here. How much odd-chain fat ordinary dog foods supply was not checked against any dog food analysis for this update. Likewise, a 2024 mini-review in Biochimie argues that the essentiality of pentadecanoic acid in humans still needs more investigation, and that debate has not been carried over to dogs at all.
Animal results also do not travel cleanly between species. In rats, circulating C15 fell as dietary total fat rose, so blood C15 does not simply track intake, and in mice C17:0 but not C15 was partly made in the body. The dolphin work on odd-chain fats comes from authors with Navy links and a pending patent [9][10][11].
Questions to Ask Before Buying
- How many milligrams of pentadecanoic acid are in the packet for my dog’s weight band?
- Has the finished product, not just the ingredient, been tested for safety or palatability in dogs, and where is it published?
- How do the inactive ingredients, including the cheese flavoring, fit my dog’s diet and any allergies?
- Does my veterinarian see any reason, given my dog’s conditions or medications, to avoid a new fatty acid supplement?
- What is the refund process if my dog refuses it or shows digestive upset?
Has Longevity15 been tested in dogs?
No dog trial of pentadecanoic acid supplementation turned up in a PubMed search in October 2026, and the product’s launch announcement cites human and general mammalian research, not a dog study. The company or your vet may hold data that is not published, so ask.
Is Longevity15 the same as Fatty15?
The active ingredient is the same FA15 pentadecanoic acid ingredient, but it is a separate dog product with different inactive ingredients, including Himalayan cheese and natural flavoring, and one packet is given daily at mealtime. The milligrams per packet were not listed in the page text read.
Where did the C15 research begin?
With dolphins. Fatty15’s FAQ says its inventor, a veterinary epidemiologist, noticed that healthier aging dolphins had higher dietary C15. That is a starting hypothesis, not evidence that C15 helps dogs.
References
- Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?. Scientific Reports, 2020
- Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of Nutrition, 2024
- Dietary pentadecanoic acid supplementation at weaning in essential fatty acid-deficient rats. The Journal of Nutritional Biochemistry, 2025
- Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3. PLOS ONE, 2022
- Venn-Watson S et al. Aging-Associated Amyloid-β Plaques and Neuroinflammation in Bottlenose Dolphins (Tursiops truncatus) and Novel Cognitive Health-Supporting Roles of Pentadecanoic Acid (C15:0). International journal of molecular sciences (2025). PMID 40332352
- Matulka RA et al. Safety evaluation of odd-chain fatty acid algal oil. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2021). PMID 34332011
- Pfeuffer M et al. Pentadecanoic and Heptadecanoic Acids: Multifaceted Odd-Chain Fatty Acids. Advances in nutrition (Bethesda, Md.) (2016). PMID 27422507
- Ciesielski V et al. New insights on pentadecanoic acid with special focus on its controversial essentiality: A mini-review. Biochimie (2024). PMID 39395658
- Benjamin Jenkins et al. The Dietary Total-Fat Content Affects the In Vivo Circulating C15:0 and C17:0 Fatty Acid Levels Independently. Nutrients (2018). PMID 30400275
- Benjamin Jenkins et al. Peroxisomal 2-Hydroxyacyl-CoA Lyase Is Involved in Endogenous Biosynthesis of Heptadecanoic Acid. Molecules (2017). PMID 29027957
- Stephanie K Venn-Watson et al. Increased Dietary Intake of Saturated Fatty Acid Heptadecanoic Acid (C17:0) Associated with Decreasing Ferritin and Alleviated Metabolic Syndrome in Dolphins. PLoS ONE (2015). PMID 26200116
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.